ABBV
US EQUITY
Health Care
Biotechnology
CIK: 1551152
AbbVie (ABBV) Quant Factor Diagnostic & Fair Value Model
AbbVie (Ticker: ABBV) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$285.64
+0.16%
Latest Close (2026-10-23)
Market Cap: $504.76B
P/E Ratio: 35.2
Momentum Strength
3M / 12M
+11.18%
1M: +7.74%
12M: +24.91%
Quality (ROE)
Point-in-Time
+15.46%
Trailing Return on Equity
Technical Trend
RSI 14
70.9
SMA50: $266.12
SMA200: $235.41
Valuation Multiplier
Trailing
35.2
Premium Multiple (> 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Premium Multiple (> 30x P/E)
ABBV trades at 35.2x P/E, reflecting market-implied growth expectations for forward revenue and cash flow.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 9/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1551152 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-08-03 | $16.99B | $3.61B | $7.26B | $2.03 |
| 10-Q | 2025-12-31 | 2026-08-03 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-08-03 | $15.42B | $938.00M | $6.79B | $0.52 |
| 10-Q | 2026-03-31 | 2026-05-08 | $15.00B | $695.00M | $3.83B | $0.39 |
| 10-Q | 2025-03-31 | 2026-05-08 | $13.34B | $1.29B | $1.64B | $0.72 |
| 10-K | 2025-12-31 | 2026-02-20 | $16.62B | $1.82B | $19.03B | $1.02 |
| 10-K | 2024-12-31 | 2026-02-20 | $15.10B | -$22.00M | $18.81B | $-0.02 |
| 10-K | 2023-12-31 | 2026-02-20 | $14.30B | $822.00M | $22.84B | $0.46 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding AbbVie (ABBV) valuation multiples, momentum factors, and point-in-time filing conventions.
How should ABBV's current valuation multiple be interpreted? ↓
ABBV trades at a trailing P/E of 35.2x within the Health Care sector (premium multiple (> 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are ABBV's key momentum and technical factor indicators? ↓
As of the latest close, ABBV shows a 1-month return of +7.74%, 3-month return of +11.18%, and 12-month return of +24.91%, with a 14-day RSI of 70.9. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for ABBV? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can ABBV be incorporated into systematic factor models? ↓
ABBV can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.